Sernova Announces Progress in Development of Regenerative Medicine Therapy

- July 24th, 2017

Sernova announced an update for its personalized regenerative medicine therapy for the treatment of Hemophilia A patients.

Sernova (TSXV:SVA; OTCQB:SEOVF) announced an update for its personalized regenerative medicine therapy for the treatment of Hemophilia A patients.
As quoted in the press release:

The therapy being developed by international scientific Consortium members consisting of three European academic institutions, an enterprise for quality management and Sernova Corp is to treat severe Hemophilia A, a serious genetic bleeding disorder caused by missing or defective clotting factor VIII in the blood stream. This therapy consists of Sernova’s implanted Cell Pouch(TM) device transplanted with therapeutic cells, corrected to produce Factor VIII at a level sufficient to significantly reduce the side effects of the disease and improve patient quality of life.

“The international HemAcure Consortium team members are pleased with the ground breaking scientific advances achieved at this point and are on track for this regenerative medicine solution to advance into human clinical evaluation,” remarked Dr. Philip Toleikis, Sernova President and CEO.  Toleikis added, “Sernova’s Cell Pouch platform technologies are achieving important world first milestones in both diabetes and now hemophilia, two significant clinical indications which are being disrupted by its regenerative medicine approach aimed at significantly improving patient quality of life.”

Click here to read the full press release.

Leave a Reply

Your email address will not be published. Required fields are marked *